Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’ ↗
UBS (UBS) stock is a hot topic among traders on Monday with one analyst offering a new rating for the financial company's shares. 
Via InvestorPlace
News headline image
Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data ↗
 
Via Benzinga
News headline image
Why Is Karuna Therapeutics (KRTX) Stock Moving Today? ↗
Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT. 
Via InvestorPlace
News headline image
Karuna Surges To Three-Month High On Another Win In Schizophrenia ↗
The company is soon planning to ask for FDA approval of KarXT. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023 ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Karuna Therapeutics ↗
 
Via Benzinga
News headline image
Looking Into Karuna Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analyst Expectations for Karuna Therapeutics's Future ↗
 
Via Benzinga
News headline image
Ciena, Apple And 3 Stocks To Watch Heading Into Monday ↗
With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Bernstein raised the price target for Okta, Inc. (NASDAQ: OKTA) from $80 to $92. Bernstein analyst Peter Weed maintained a Market Perform rating. Okta shares jumped 16.2% to $83.00 in pre-market... 
Via Benzinga
News headline image
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗
 
Via Benzinga
5 Analysts Have This to Say About Karuna Therapeutics ↗
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Karuna Therapeutics ↗
 
Via Benzinga
Where Karuna Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
Expert Ratings for Karuna Therapeutics ↗
 
Via Benzinga
News headline image
Why Karuna Therapeutics Shares Are Trading Sharply Lower ↗
Karuna Therapeutics Inc (NASDAQ: KRTX) shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition. What Happened? 
Via Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
My 3 Top Biotech Stock Picks for 2023 ↗
Biotech stocks are set to shine in 2023. 
Via The Motley Fool
News headline image
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
News headline image
Karuna Therapeutics: Q3 Earnings Insights ↗
Karuna Therapeutics (NASDAQ:KRTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
What 12 Analyst Ratings Have To Say About Karuna Therapeutics ↗
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
12 Analysts Have This to Say About Karuna Therapeutics ↗
Within the last quarter, Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
2 On-Fire Biotech Stocks That Are Crushing the Bear Market ↗
The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns. 
Via The Motley Fool
News headline image
Opportunities In Large Cap Growth And Small Cap ↗
The third quarter was true 
Via Talk Markets
News headline image
Biotech Stocks Well-Positioned For The Fourth Quarter ↗
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
News headline image
Where Karuna Therapeutics Stands With Analysts ↗
Over the past 3 months, 12 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
7 Momentum Stocks to Buy Now for Extraordinary Gains ↗
Momentum stocks aren't as risky as some say, and these winning stocks are strong examples for investors to consider. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.